Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alexion’s Soliris REMS Gets FDA Panel Review In Wider Evaluation Effort

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee will revisit REMS for ultra-rare disease drug as part of larger agency effort to evaluate the effectiveness of the safety programs.

You may also be interested in...

Unintended Consequences Of REMS Weighed On Entyvio Review Team

FDA chose to focus on communication instead of use restrictions to manage PML risk with Takeda’s Entyvio after looking long and hard at REMS options and the potential unintended effects of the risk management plans on drug utilization.

Alexion’s Costly Soliris For AHUS Raises “Cost Of Life” Issues At NICE

NICE is undeniably impressed with Alexion’s Soliris for treating aHUS but wants more data to justify its eye-watering price tag.

REMS Need Metrics For Assessing Success, Burden On Health Care System

“We don’t really have clear methods for assessing burden and access,” CDER’s Mary Willy acknowledges. A lack of baseline information hinders the measurement of whether REMS and their components are working.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts